Abstract
Aim: MK-8591 (EFdA), a novel anti-HIV nucleoside analog, is converted to mono-, di- and tri-phosphates (MK-8591-MP, MK-8591-DP and MK-8591-TP) intracellularly, among which MK-8591-TP is the active pharmacological form. An ultrasensitive LC–MS/MS assay was required to measure MK-8591-DP and MK-8591-TP levels in human peripheral blood mononuclear cells (PBMCs). Sensitivity and reproducibility were major bottlenecks in these analyses. Materials and methods: Human PBMCs were isolated from blood and lysed with 70/30 methanol/RPMI-1640. An LC–MS/MS method was developed to simultaneously quantify MK-8591-DP and MK-8581-TP in PBMC lysates. Results: Low flow LC and dimethyl sulfoxide mediated signal enhancement enabled an extreme sensitivity with limit of quantitation at 0.1 ng/ml. Assay accuracy was 92.5–106% and precision was 0.7–12.1% for a linear curve range of 0.1–40 ng/ml. Matrix variability and interference liability were comprehensively evaluated. Conclusion: Our study findings and steps taken in addressing clinical sample issues help understand and overcome the challenges facing intracellular nucleotide analog analysis.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1 . Mitsuya H 2′-deoxy-4′-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against wide spectrum of HIV-1 strains, favorable toxic profiles, and stability in plasma. Nucleosides, Nucleotides and Nucleic Acids. 26(10–12), 1543–1546 (2007).
- 2 . 2′-deoxy′4′-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity. Chem. Record. 6, 133–143 (2006).
- 3 Long-acting oral and parenteral dosing of MK-8591 for HIV treatment or prophylaxis. Presented at: CROI. Boston, MA, USA (2016).
- 4 . Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs. Mass Spectrom. Rev. 30, 321–343 (2011). •• An overview of nucleotide analog analysis by LC–MS/MS based methods.
- 5 . Quantification of zidovudine and individual zidovudine phosphates in peripheral blood mononuclear cells by a combined isocratic high performance liquid chromatography radioimmunoassay method. J. Pharm. Biomed. Anal. 14(4), 491–499 (1996).
- 6 Development of a direct assay for measuring intracellular AZT triphosphate in humans peripheral blood mononuclear cells. Anal. Chem. 74(16), 4220–4227 (2002).
- 7 . A direct determination of thymidine triphosphate concentrations without dephosphorylation in peripheral blood mononuclear cells by LC/MS/MS. J. Pharm, Biomed. Anal. 26(5–6), 829–836 (2001).
- 8 . Simultaneous quantitation of the nucleotide analog adefovir, its phosphorylated anabolites and 2′-deoxyadenosine triphosphate by ion-pairing LC/MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 848(2), 335–343 (2007).
- 9 Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. J. Mass Spectrom. 41, 1633–1642 (2006).
- 10 . Development and validation of an assay for the quantitative determination of cladribine nucleotides in MDCKII cells and culture medium using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. Rapid Commun. Mass Spectrom. 21, 4049–4059 (2007).
- 11 Improved ruggedness of an ion-pairing liquid chromatography/tandem mass spectrometry assay for the quantitative analysis of the triphosphate metabolite of a nucleoside reverse transcriptase inhibitor in peripheral blood mononuclear cells. Rapid Commun. Mass Spectrom. 27, 481–488 (2013).
- 12 . Positive ion electrospray ionization tandem mass spectrometry coupled to ion-pairing high-performance liquid chromatography with a phosphate buffer for the quantitative analysis of intracellular nucleotides. Rapid Commun. Mass Spectrom. 14, 1625–1634 (2000).
- 13 . Liquid chromatographic analysis of nucleosides and their mono-, di- and triphosphates using porous graphitic carbon stationary phase coupled with electrospray mass spectrometry. Rapid Commun. Mass Spectrom. 18, 1599–1606 (2004).
- 14 . Ultrasensitive method to quantify intracellular zidovudine mono-, di- and triphosphate concentrations in peripheral blood mononuclear cells by liquid chromatography–tandem mass spectrometry. J. Mass Spectrom. 50, 783–791 (2015).
- 15 . Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC–MS/MS. J. Pharm, Biomed. Anal. 86, 198–203 (2013).
- 16 . HILIC LC–MS for the determination of 2′-C-methyl-cytidine-triphosphate in rat liver. J. Sep. Sci. 32, 1275–1283 (2009).
- 17 A strategy for liquid chromatography/tandem mass spectrometric assays of intracellular drugs: application to the validation of the triphosphorylated anabolite of antiretrovirals in peripheral blood mononuclear cells. J. Mass Spectrom. 38, 879–890 (2003). • LC–MS/MS validation considerations for intracellular analysis of triphosphorylated antiretrovirals described.
- 18 DMSO enhances electrospray response, boosting sensitivity of proteomic experiments. Nat. Meth. 10(10), 989–991 (2013). •• DMSO mediated electrospray ionization response enhancement for proteomic experiments described.
- 19 . Charge state coalescence during electrospray ionization improves peptide identification by tandem mass spectrometry. J. Am. Soc. Mass Spectrom. 23, 1390–1399 (2012).
- 20 . In-spray supercharging of peptides and proteins in electrospray ionization mass spectrometry. Anal. Chem. 84, 4647–4651 (2012).
- 21 . Can DMSO provide benefit in application beyond proteomics? Presented at: ASMS 2014. Baltimore, MD, USA (2014).
- 22 . Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 140, 1–22 (1994).